GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the successful completion of a EUR 2,894,715.96 fundraising subscribed by three of its shareholders: Heights Capital, Invus and Alumni Capital (the “Fundraising”). This fundraising follows the EUR 4.5 million private placement completed in July (in two tranches), the EUR 3.7 million fundraising completed in early October and the EUR 2 million fundraising completed in November. The Fundraising uses the same structure of shares and warrants, including pre-funded warrants, as detailed further below.
“2025 has been a transformative year for GenSight Biologics. Securing compassionate use approvals in three major markets-the United States, France, and Israel-represent a significant regulatory milestone,” said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. “These achievements, soon to be capped with the completion of our manufacturing technology transfer in December 2025, give us tremendous momentum to take into the coming year. I want to extend my deepest gratitude to our shareholders for their steadfast support throughout 2025 and in this latest financing round. Their commitment enables us to execute our vision, and we look forward to passing numerous exciting milestones throughout 2026 as we continue to advance our mission.”
Also Read: Accenture Acquires Cabel Industry to Boost Fintech
The Fundraising is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des marchés financiers – the “AMF”). However, in accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the “Prospectus Regulation”), the Company will file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the “Information Document”) for the purpose of the listing on the regulated market of Euronext in Paris (“Euronext Paris”) of the Offered Shares, the Pre-Funded Warrant Shares and the Investor Warrant Shares (as defined below) to be issued in the context of the Fundraising.
“The various bridge financing rounds since early 2024 demonstrate the unwavering confidence of our investors, enabling us to advance steadily with our programs,” said Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. “The compassionate use approvals secured in the United States, France, and Israel mark an inflection point that positions us well for our next phase of growth.”
SOURCE: Businesswire